Please use this identifier to cite or link to this item:
|Title:||What is the optimal GnRH antagonist protocol for ovarian stimulation during ART treatment? A systematic review and network meta-analysis.||Austin Authors:||Venetis, C A;Storr, A;Chua, S J;Mol, B W;Longobardi, S;Yin, X;D'Hooghe, T||Affiliation:||University of New South Wales, Faculty of Medicine & Health, Centre for Big Data Research in Health & Discipline of Obstetrics and Gynaecology, Sydney, Australia.
Flinders Fertility, Adelaide, SA, Australia.
Department of Obstetrics and Gynaecology, Monash University, Clayton, Australia.
Global Clinical Development, Merck Serono S.p.A, Rome, Italy, an affiliate of Merck KGaA.
EMD Serono Inc., R&D Global Biostatistics, Epidemiology & Medical Writing, Billerica, MA, USA, an affiliate of Merck KGaA.
Merck Healthcare KGaA, Darmstadt, Germany.
|Issue Date:||3-Jan-2023||metadata.dc.date:||2023||Publication information:||Human Reproduction Update 2023||Abstract:||Several GnRH antagonist protocols are currently used during COS in the context of ART treatments; however, questions remain regarding whether these protocols are comparable in terms of efficacy and safety.||URI:||https://ahro.austin.org.au/austinjspui/handle/1/31945||DOI:||10.1093/humupd/dmac040||ORCID:||0000-0001-9591-7222
|Journal:||Human Reproduction Update||PubMed URL:||36594696||ISSN:||1460-2369||Type:||Journal Article||Subjects:||ART
assisted reproductive technologies
controlled ovarian stimulation
|Appears in Collections:||Journal articles|
Show full item record
checked on Jun 7, 2023
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.